Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Daxor Corp DXR

Healthcare Medical Devices
Daxor Corporation is a blood volume measurement technology company, which is focused on blood volume testing innovation. The Company has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific... see more

Recent & Breaking News (NDAQ:DXR)

New Study Demonstrates Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes

GlobeNewswire May 18, 2023

New Studies Presented at the 43rd International Society for Heart and Lung Transplant Validate the Applicability of the BVA-100® Blood Test for Patients with Advanced Heart Failure

GlobeNewswire April 20, 2023

Daxor Corporation to Exhibit at the MedAxiom Cardiovascular Transforum Conference Spring'23 to Advance Awareness and Further Adoption of Daxor's Blood Volume Diagnostic (BVA-100®)

GlobeNewswire April 17, 2023

Daxor Corporation to Exhibit at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

GlobeNewswire April 13, 2023

Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100® Blood Volume Diagnostic for Heart Failure Patients

GlobeNewswire March 27, 2023

New Study Confirms Daxor's BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients

GlobeNewswire March 23, 2023

Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients

GlobeNewswire March 23, 2023

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

GlobeNewswire March 3, 2023

Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022

GlobeNewswire March 2, 2023

Daxor Corporation to Report Fiscal Year 2022 Financial Results on Wednesday, March 1, 2023 and Provide Corporate Update

GlobeNewswire March 1, 2023

Daxor Corporation Appoints Linda Cooper, Vice President Project Management

GlobeNewswire February 17, 2023

Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member

GlobeNewswire January 19, 2023

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress

GlobeNewswire January 13, 2023

Newly Published Study Proves Value and Clinical Benefit of Daxor's Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure

GlobeNewswire January 3, 2023

Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option

GlobeNewswire November 17, 2022

Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering

GlobeNewswire November 15, 2022

Daxor Corporation Announces Launch of Proposed Underwritten Public Offering

GlobeNewswire November 14, 2022

Live Webinar by MedAxiom Features Best Practices Using Daxor's Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs

GlobeNewswire November 10, 2022

Newly Published Study Demonstrates Significant Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure

GlobeNewswire November 3, 2022

Daxor Corporation to Exhibit at American Heart Association's Scientific Sessions 2022

GlobeNewswire October 31, 2022